SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 18, 2021
Encompass Health Corporation
(Exact name of Registrant as specified in its Charter)
(State or Other Jurisdiction of Incorporation)
|(Commission File Number)||(IRS Employer Identification No.)|
9001 Liberty Parkway, Birmingham, Alabama 35242
(Address of Principal Executive Offices, Including Zip Code)
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, par value $0.01 per share||EHC||New York Stock Exchange|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 21, 2021, Encompass Health Corporation (the “Corporation”) announced the appointment of Ms. Barbara A. Jacobsmeyer, the current President, Inpatient Hospitals of the Corporation, as the Chief Executive Officer, Home Health and Hospice. She will continue to report directly to Mr. Mark J. Tarr, President and Chief Executive Officer of the Corporation. Ms. Jacobsmeyer succeeds Ms. April K. Anthony, whose previously announced departure was effective June 18, 2021.
In connection with her new responsibilities, the Compensation and Human Capital Committee of the Corporation’s Board of Directors approved on June 18, 2021 an increase in Ms. Jacobsmeyer’s annual base salary from $650,000 to $750,000 effective June 21, 2021.
Except as noted above, Ms. Jacobsmeyer’s employment and compensation arrangements, including participation in incentive award plans, and benefits remain substantially the same as previously discussed in more detail in the Executive Compensation section of the Corporation’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 26, 2021.
Item 7.01. Regulation FD Disclosure.
On June 21, 2021, the Corporation issued a press release, attached hereto as Exhibit 99.1, announcing the leadership succession in its home health and hospice segment.
The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|ENCOMPASS HEALTH CORPORATION|
/S/ Patrick Darby
|Title:||Executive Vice President, General Counsel and Secretary|
Dated: June 21, 2021